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ABSTRACT
Objectives The primary objective was to compare the 
efficacy of enteral potassium replacement (EPR) and 
intravenous potassium replacement (IVPR) as first-line 
therapy. Secondary objectives included comparison of 
adverse effects and number of doses required to resolve the 
episode of hypokalaemia.
Trial design The EIPS trial is designed as a randomised, 
equivalence trial between two treatment arms.
Study setting The study was conducted at the paediatric 
cardiac intensive care unit (PCICU) at Aga Khan University 
Hospital, Karachi.
Participants 41 patients (aged 1 month to 15 years) who 
were admitted to PCICU post cardiac surgery were recruited 
(23 IVPR arm and 18 EPR arm).
Intervention Intervention arms were block randomised on 
alternate weeks for IVPR and EPR.
Outcome measure Change in serum potassium levels 
in (mmol/L) and percentage change after each event of 
potassium replacement by the intravenous or enteral route.
Results Both groups (41 patients) had similar baseline 
characteristics. Mean age was 4.7 (SD±4) years while 
the most common surgical procedure was ventricular 
septal defect repair (12 patients, 29.3%). No mortality was 
observed in either arm. Four episodes of vomiting and one 
arrhythmia were seen in the EPR group. After adjusting for 
age, potassium level at the beginning of the episode, average 
urine output, inotropic score and diuretic dose, it was found 
that there was no statistically significant difference in change 
in potassium levels after EPR and IVPR: 0.86 mmol/L (±0.8) 
and 0.82 mmol/L (±0.7) respectively (p=0.86, 95% CI −0.08 
to 1.10), or percentage change in potassium level after 
enteral and intravenous replacement: 26% (±30) and 24% 
(±20) (95% CI −3.42 to 4.03, p=0.87).
Conclusion EPR may be an equally efficacious alternative 
first-line therapy in treating hypokalaemia after surgery in 
selective patients with congenital heart disease.
Ethics and dissemination This study has been approved 
by Ethics Review Committee at AKU.
Trial registration number NCT02015962.
INTRODUCTION
Hypokalaemia is a frequently encountered 
electrolyte abnormality in the daily clinical 
practice of the paediatric cardiac intensive 
care unit (PCICU). In the postoperative 
period, activation of the renin–angiotensin–
aldosterone system, enhanced sympathetic 
tone and use of potassium-wasting diuretics 
for positive fluid balance have led to 
increased occurrence of severe hypokalaemia 
and its consequences.1 Hypokalaemia is a 
strong independent predictor of mortality 
in patients with heart failure.2–4 Potassium 
replacement remains the cornerstone therapy 
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Strengths and limitations of this study
 ► EIPS is the first prospective randomised equivalence 
trial comparing the routes (enteral vs  intravenous) 
for potassium replacement in paediatric patients in 
intensive care post cardiac surgery.
 ► A retrospective review has previously shown 
comparable efficacy between the two routes.
 ► Research from this trial will lead the way for further 
research in this field, possibly bringing about a 
change in the management of hypokalaemia in 
patients after surgery and subsequently lower 
complications and morbidity associated with 
intravenous potassium replacement.
 ► EIPS is not a blinded study, which may lead to a 
procedure bias. Blinding could not be carried out in 
this trial owing to different routes of administration of 
the same supplementation (enteral vs intravenous) 
and different time intervals for checking serum levels 
in each arm (1 hour after intravenous replacement 
and 2 hour after enteral replacement).
 ► Confounding factors, such as concomitant use of 
diuretics and inotropic agents during the episode, 
were identified and adjusted in the analysis.
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for hypokalaemia. There is mounting evidence that the 
serum potassium level should be maintained between 
3.5 and 4.5 mmol/L5 or even higher in the setting of 
acute cardiac injury.6 7 Thus it is highly desirable to avoid 
hypokalaemia by close monitoring and subsequent potas-
sium replacement.
Although intravenous potassium replacement (IVPR) 
in hypokalaemia is the preferred route in most inten-
sive care settings, it is associated with known safety risks. 
IVPR can lead to arrhythmias, cardiac arrest and death if 
administered inappropriately.2 8 9 Given these risks, IVPR 
is considered a ‘high-alert medication’ by the Institute 
of Safe Medication practice.10 11 The need to maintain 
and frequently access a central line for administration of 
higher concentrations of potassium can lead to serious 
central line infections. Inability to use high-concentra-
tion potassium through peripheral lines may lead to 
administration of a larger volume of fluid for the delivery 
of the desired dose of potassium, thus disturbing the 
fluid balance in these patients. This may be detrimental 
in cardiac patients after surgery in whom a negative fluid 
balance is optimal. Given all the above mentioned issues 
with IVPR, enteral potassium replacement (EPR), with 
its equal or superior safety profile, may be a better alter-
native to IVPR. A retrospective review showed that the 
efficacy of EPR was comparable to IVPR in paediatric 
patients after surgery for congenital heart disease.9
We sought to explore this comparison between EPR 
and IVPR in a randomised equivalence trial to determine 
if EPR can be used as an alternative to IVPR.
This trial was registered at  ClinicalTrials. gov (registra-
tion number: NCT02015962). This manuscript describes 
the results of the trial. Consort checklist of the trial is 
also included as supplementary file. Details of the trial 
protocol and design have been previously published.12
OBJECTIVES
The primary objective was to compare the equivalence 
of efficacy (measured as change in serum potassium 
levels in mmol/L and percentage change in level after 
potassium replacement) between EPR and IVPR as first-
line therapy for the treatment of hypokalaemia. The 
secondary objectives were to compare the adverse effects 
(hyperkalaemia, diarrhoea, gastrointestinal bleeds, 
nausea and vomiting) after EPR and IVPR; to compare 
the number of doses required in achieving resolution 
of hypokalaemia (as described per protocol) for each 
episode; and to determine the efficacy of EPR versus 
IVPR for various degrees of severity of hypokalaemia, 
that is, mild, moderate or severe.
We hypothesise that EPR will be equally efficacious 
in the treatment of hypokalaemia as IVPR, as first-line 
therapy.
TRIAL DESIGN
Trial protocol and design have been published previ-
ously.12 Briefly, the EIPS trial was designed as a 
randomised, non-blinded, equivalence trial with two 
arms. Arm A (IVPR) received intravenous potassium 
replacement while Arm B (EPR) received enteral potas-
sium replacement as a treatment for hypokalaemia. 
Intervention arms were block randomised in alternate 
weeks for IVPR and EPR for the sake of convenience 
and to minimise error in drug delivery.
METHODS
Definitions used for the study
Hypokalaemia
Hypokalaemia was defined as serum potassium 
<4.4 mmol/L
Event and episode of hypokalaemia
Serum potassium <4.4 mmol/L was considered as hypo-
kalaemia. This marked the beginning of an episode of 
hypokalaemia. Each potassium replacement was consid-
ered an event of hypokalaemia irrespective of whether 
hypokalaemia was completely resolved or not. The 
episode of hypokalaemia ended when the potassium 
level returned to the normal range as described above.
Study setting
The study was conducted in the paediatric cardiac inten-
sive care unit (PCICU) at Aga Khan University Hospital, 
Karachi, Pakistan.
Eligibility criteria
Inclusion criteria
This trial included patients, aged 1 month to 15 years, 
undergoing surgical repair/palliation of a congen-
ital heart lesion at Aga Khan University Hospital and 
admitted to the PCICU for postoperative management. 
Patients'/parents' willingness to participate in this study, 
serum potassium levels <4.4 mmol/L in the postoperative 
period, ability to tolerate oral or nasogastric administra-
tion of medication for EPR and presence of a central line 
for IVPR were also included in the eligibility criteria.
Exclusion criteria
We excluded patients with acute renal failure (creati-
nine clearance: ecCr <75%, urine output <0.3 mL/
kg/hour×16 hours).13 Patients with paralytic ileus, 
necrotising enterocolitis, gastrointestinal bleeding, 
nausea, vomiting or diarrhoea were also excluded as 
they could not be given EPR. However, patients were 
not excluded if vomiting or diarrhoea developed after 
initial recruitment. Patients with critically low serum 
potassium <2.0 mmol and patients with symptomatic 
hypokalaemia were not recruited.
Consent procedure
Informed consent and assent was obtained by investiga-
tors from each patient (or parents) before cardiac surgery.
Study recruitment, procedure and monitoring
A detailed description of recruitment, study proce-
dure and monitoring has been previously published.12 
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Patients were enrolled and potassium levels were checked 
routinely once they were moved to PCICU postopera-
tively. When the patients developed hypokalaemia, they 
received treatment according to the intervention arm 
and were followed until they had reached optimal potas-
sium levels or moved from PCICU to a step-down unit. 
Repeat serum potassium levels were checked 1 hour 
after replacement in the IVPR group and 2 hours after 
replacement in the EPR group. Further monitoring of 
the serum electrolytes was determined by the patient’s 
clinical status.
In cases when the patient stayed in PCICU for longer 
than 1 week and block changed, patients continued 
to follow the route they were originally assigned. EPR 
patients who developed side effects (eg, vomiting, 
gastrointestinal upset) or critically low levels of potas-
sium <2 mmol (exclusion criteria) were allowed to cross 
over and receive IVPR. An intention to treat analysis was 
performed to account for crossover patients.
During the pre-recruitment trial period, it was 
recognised that patients who were given enteral potas-
sium supplementation could not tolerate the enteral 
formulation and ended up vomiting due to the sour 
taste of the formulation. Thus it was decided to admin-
ister enteral potassium through a nasogastric (NG) 
tube, placed intraoperatively, in mechanically ventilated 
patients. Once patients were extubated and started 
tolerating oral feeds, enteral potassium supplementa-
tion was administered with apple juice to improve the 
taste and palatability of the medicine. These measures 
were adopted throughout the trial to improve tolerance 
and compliance to EPR.
Study drugs, drug management
Drug-dosing protocol for potassium replacement is 
shown in table 1; details about the maximum concen-
tration, dose in each arm and drug management can be 
reviewed in a previously published protocol.12
Intravenous potassium chloride
The maximum dose was 3 mmol/kg/day. The dilution 
and infusion rate was 8 mmol/100 mL, 10 mmol/hour for 
a peripheral line; 15 mmol/100 mL, 15 mmol/hour for 
a central line.
Oral potassium chloride
The maximum dose was 240 mmol/24 hours. 
The maximum per dose was 60 mmol. The concentration 
was 13.33 mmol/5 mL.
Adverse events
The adverse effects of potassium supplementation that 
were monitored included hyperkalaemia (potassium 
levels >5 mmol/L), arrhythmias, diarrhoea, gastrointes-
tinal bleeds and nausea and vomiting, during or within 
2 hours of potassium replacement.
The adverse events were monitored and documented 
on an hourly basis by PCICU nursing staff and notified to 
on-call physicians and the principal investigator.
Sample size calculation
The sample size was calculated using an equivalence 
test of mean procedure, considering both interventions 
(EPR and IVPR) were of equal efficacy with an SD of 
4%. The equivalence limit was assumed to be ±(15%), 
using a power of 90% and a level of significance of 5%; 
a total of 155 events were required in each arm to reject 
the null hypothesis which states that there is no differ-
ence in efficacy (change in serum potassium levels) of 
IVPR and EPR. The sample size was calculated using 
PASS software.
Statistical analysis
The primary objective of the study was to compare the 
efficacy of EPR and IVPR as a first-line therapy for the treat-
ment of hypokalaemia. The end points (primary outcome) 
used were change in serum potassium levels in mmol/L 
and percentage change in serum potassium levels after 
each event of potassium replacement by both methods.
Data were analysed using two approaches: intention 
to treat (ITT) and actual treatment (AT) received anal-
ysis. ITT was considered the primary analysis. The mean 
(±SD) was calculated for continuous parametric vari-
ables while the median was used to describe continuous 
non-parametric variables. Categorical variables are 
presented as frequencies. To explore bivariate associa-
tions, the independent Student t and Mann-Whitney 
U tests were used for parametric and non-parametric 
continuous variables respectively, while χ2 was used for 
categorical variables. Change in potassium concentra-
tion over time was assessed by mixed effects regression 
modelling; this incorporated a random intercept trend. 
This analytic approach included all participants who had 
data available on at least one time point. A hierarchical 
model was developed that nests an event within an episode 
and patients through random intercept modelling to 
adjust for inter-individual and episode-related variation 
in change in potassium concentration. The analysis 
included linear time effect with main effect of treatment 
to examine whether the experimental condition (EPR) 
resulted in greater changes in potassium than the control 
(IVPR) over time. Age of participants, potassium concen-
tration at beginning of episode, average urine output, 
Table 1 Potassium replacement dosing
Serum potassium level 
(mmol/L)
Potassium replacement 
(intravenous and enteral)
4.0–4.4 0.1 mmol/kg/dose
3.5–3.9 0.3 mmol/kg/dose
3.0–3.4 0.5 mmol/kg/dose
2.5–2.9 0.7 mmol/kg/dose
2.1–2.4 1 mmol/kg/dose and call physician
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diuretic dose and inotrope score were incorporated in 
the model as confounding factors and the results were 
reported as coefficients with 95% CIs. Data were analysed 
using STATA version 12 through xtmixed command. 
The model building command includes three steps. 
As a first step an unconditional model was tested with 
episode and event level random intercepts to examine 
the variation in outcomes at these levels. In the next 
step, a time variable was added with outcome as a fixed 
effect and random slope. A likelihood ratio (LR) test 
was used to confirm whether the variance of the slope is 
significantly different from zero. Time was treated as a 
fixed effect when the LR test failed to provide evidence 
for this null hypothesis. Finally, outcome adjusted for all 
potential covariates significant at a liberal p<0.2 in bivar-
iate analysis were retained if significant at p<0.05. Fit of 
the models was assessed through Akaike information 
criteria (AIC) and Bayesian information criteria (BIC). 
Generally the smaller the statistical value, the better the 
model fits the data.
An interim analysis was performed after 155 events 
(cumulative in both arms) to ensure protocol compli-
ance and to monitor adverse effects. Analysis did not 
reveal any major adverse effects and validated compa-
rable efficacy between the two arms. Thus, no major 
changes were made to the protocol and the trial was 
continued to achieve the final sample size.
Data collection, storage and record keeping
The data abstraction form was used to abstract patient 
data for the study.
Data were collected by investigators (NR, QM, AR) 
throughout the duration of the study and were kept safe 
under lock and password protected e-files at all times.
Ethics committee and regulatory approval
This study was approved by the ERC and Clinical Trials 
Unit at Aga Khan University Hospital.
RESULTS
Patients were recruited from December 2013 to May 
2014. Initially 55 patients were approached. The first 
10 patients were recruited and consented to participate 
in the pre-trial period; they were not included in the 
trial analysis. During the pre-trial period, the EPR and 
IVPR potassium protocol was introduced for the training 
of staff nurses. The next 45 patients were recruited 
for the trial. Of these, four were excluded as they did 
not meet the inclusion criteria (two participants were 
excluded as they developed critically low levels of potas-
sium, while the other two participants did not develop 
an episode of hypokalaemia during their PCICU stay). 
Thus 41 patients fulfilled the inclusion criteria for the 
trial. There was no attrition from the patients recruited. 
The most common cardiac lesion in both the groups 
was found to be a ventricular septal defect (VSD) and 
the most common surgical procedure was VSD closure. 
None of the patients received continuous or modified 
ultrafiltration during or after surgery. After randomis-
ation, 18 patients were recruited to the IVPR arm and 
23 patients to the EPR arm. The mean age of patients 
was 4.8 (SD ±4) in the IVPR group and 4.6 (SD ±4.0) in 
the EPR group (table 2a).
Five patients from the EPR arm crossed over to 
the IVPR arm (figure 1) due to development of 
adverse events: four vomiting and one arrhythmia. 
The median length of PCICU stay was 2 (0.63–14) days 
and 1.95 (0.58–8) days (p=0.26) in the IVPR and EPR 
arms respectively. The median length of hospital stay 
for the IVPR arm was 7 (3–19) days while in the EPR 
arm it was 6 (4–18) days (p=0.83). A total of 97 episodes 
of hypokalaemia were recorded (48 and 49 in the IVPR 
and EPR arms respectively). From these episodes, a total 
of 460 events of hypokalaemia were recorded (234 and 
226 in the IVPR and EPR arms respectively). There was 
no difference in episodes (IVPR 2.7, SD ±2.1; EPR 2.1, 
SD ±1.3) and events (number of doses) (IVPR 5.0, SD 
±4.9; EPR 4.6, SD ±4.2) per child between the two arms 
(table 2b).
Mode of supplementation and response to therapy
There was no difference between IVPR and EPR arms 
in the mean serum potassium levels at the beginning 
(3.67±0.42 vs 3.62±0.48, p=0.45 respectively) and at 
the end of the episode of hypokalaemia (4.47±0.62 vs 
4.48±0.60, p=0.94 respectively) (figure 2).
Univariate analysis showed no difference in response 
to therapy (number of doses required, absolute change 
(intravenous 0.82±0.7; 95% CI 0.62 to 1.01 vs oral 0.86±0.8; 
95% CI 0.62 to 1.10; p=0.8) and percentage change (intra-
venous 24±20; 95% CI 18 to 30 vs oral 26±30; 95% CI 18 to 
35; p=0.59) in potassium levels in both arms at the initial 
episode (table 2b). The overall difference of relative 
change in potassium concentration was −2.7% (95% CI 
−12.8% to 7.3%) with ITT analysis which was within the 
predetermined equivalence limit (±15%).
Actual treatment received analysis was also performed 
and findings were not significantly different from ITT 
analysis.
Using repeated measures analysis, after adjusting for the 
age of the patient, potassium concentration at the begin-
ning of the episode, average urine output, inotropic score 
and diuretic dose, the change in absolute potassium level 
for each event of hypokalaemia was equal with no statisti-
cally significant difference between the two arms for ITT 
(β=0.01; 95% CI −0.08 to 0.10; p=0.86) and actual treat-
ment analysis. Similar results were seen when analysis was 
performed using percentage change in potassium levels 
after supplementation for ITT (β=0.30; 95% CI −3.42 to 
4.03, p=0.87) and actual treatment analysis (table 3, see 
online supplementary table 1, table 2, table 3).
Linear mixed effect regression analysis was adjusted 
for episode level variations and controlled for covariates 
of age, potassium levels at the beginning of the episode, 
inotropic score, average urine output and average diuretic 
dose. The β coefficient is the standardised coefficient’ 
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Table 2a Baseline characteristics of enrolled children in IVPR and EPR arms
Intention to treat (ITT) Actual treatment received(AT)
Intravenous K (n=18) Oral K (n=23) p-value Intravenous K (n=23) Oral K (n=18) p-value
Age at randomisation 
(count, %)
<1 year 5 (27.8%) 4 (17.4%) 0.54 6 (26.1%) 3 (16.7%) 0.61
1–5 years 5 (27.8%) 10 (43.5%) 7 (30.4%) 8 (44.4%)
5–15 years 8 (44.4%) 9 (39.1%) 10 (43.5%) 7 (38.9%)
Mean age (years)* 4.8±4.0 4.6±4.0 0.91 4.8±4.2 4.6±3.8 0.87
Indicators at beginning of 
episode
Potassium level 
(count, %)†
Mild 33 (71.7%) 31 (63.3%) 0.47 41 (74.5%) 23 (57.5%) 0.14
Moderate 13 (28.3%) 17 (34.7%) 14 (25.5%) 16 (40.0%)
Severe – 1 (2.0%) – 1 (2.5%)
Mean potassium* 3.7±0.5
(3.5 to 3.8)
3.6±0.5
(3.5 to 3.8)
0.71 3.7±0.5
(3.6 to 3.8)
3.6±0.5
(3.4 to 3.7)
0.23
Average urine output (ml/
kg/hour)*
3.9±2.1
(3.4–4.6)
4.3±2.5
(3.6–5.0)
0.44 4.1±2.2
(3.5–4.7)
4.2±2.5
(3.4–5.0)
0.81
Diuretic average dose 
(mg/kg)*‡
0.4±0.5
(0.3–0.6)
0.4±0.6
(0.2–0.5)
0.57 0.5±0.6
(0.3–0.6)
0.3±0.4
(0.2–0.4)
0.15
Inotrope score* 8.5±9.1
(5.5–10.7)
4.6±4.1
(3.4–5.8)
0.01 8.4±8.8
(5.6–10.5)
4.1±3.3
(3.0–5.1)
0.004
Total episodes 48 49 57 40
*Values reported as mean±SD (95% CI)
†Severity of hypokalaemia defined as potassium level of mild: 3.5–4.4 mEq/L, moderate: 2.5–3.4 mEq/L, severe: 2.1–2.4 mEq/L
‡Diuretics were given either at bolus every 6 hours or as a continuous infusion. Average dose was calculated as total diuretic (mg) received in 
6 hours/ weight (kg) of the patient/6 to get mg/kg/hour.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.
Figure 1 Recruitment flow chart EIPS.
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showing the degree of impact of intervention on the 
outcome.
Adverse events
No mortality occurred in either of the arms. A total of five 
adverse events were observed in the EPR arm while none 
were recorded in the IVPR arm. Out of these five cases, four 
were episodes of vomiting within 2 hours of enteral potas-
sium replacement. A single atrial arrhythmia occurred in 
a 4.5 month old patient who underwent complete repair 
for tetralogy of Fallot. Abnormal rhythm was noticed an 
hour after enteral supplementation for treating mild hypo-
kalaemia. Rhythm was evaluated to be a run of ectopic 
atrial tachycardia. This patient was also noted to have such 
episodes of tachycardia in the immediate postoperative 
period before the enteral supplementation was started. 
The rhythm improved after the patient was placed on oral 
amiodarone. No episodes of hyperkalaemia were appreci-
ated.
DISCUSSION
Our trial portrays comparable efficacy of both the modes 
of supplementation, intravenous and enteral, as first-line 
therapy for the correction of hypokalaemia in paediatric 
patients in the PCICU setting post cardiac surgery. 
Through this trial we were able to establish that enteral 
potassium supplementation is an equally efficacious and 
safe mode of potassium replacement as first-line therapy 
during hypokalaemia in selected patients with congen-
ital heart disease in the immediate postoperative period.
Paediatric patients, after congenital heart disease 
repair, are particularly susceptible to hypokalaemia in 
the postoperative period due to administration of high 
doses of loop diuretics and inotropes.1 7 In the imme-
diate postoperative period, the body does not conserve 
potassium efficiently, thus making potassium supplemen-
tation a requirement for many such paediatric patients 
after cardiac surgery.1 Potassium supplementation has 
a narrow therapeutic range and thus a guarded safety 
profile. Although serious adverse effects with either 
mode of supplementation are quite rare, inappropriate 
administration of potassium in these patients may lead to 
worsening of heart failure, cardiac arrest, hyperkalaemia, 
arrhythmias and death.2 8 9 Given all the above mentioned 
factors, efficient potassium replacement through a safe 
route holds pivotal importance in paediatric patients 
after cardiac surgery.
Table 2b Episodes, events and mean percentage change in potassium concentration in the IVPR and EPR arms
Intention to treat (ITT) Actual treatment received(AT)
Intravenous K Oral K p-value* Intravenous K Oral K p-value*
Events 234 226 279 181
Episode per child (N) 18 23 23 18
Mean±SD 2.7±2.1 2.1±1.3 0.32 2.5±1.9 2.2±1.4 0.63
Event per episode (N) 48 49 57 40
Mean±SD 5.0±4.9 4.6±4.2 0.70 5.0±4.8 4.5±4.2 0.64
Change in potassium (N)† 48 49 57 40
Mean±SD
95% CI
0.82±0.7
(0.62 to 1.01)
0.86±0.8
(0.62 to 1.10)
0.80 0.78±0.6
(0.65 to 0.95)
0.93±0.8
(0.64 to 1.21)
0.34
Relative percentage change 
in potassium (N)‡
48 49 57 40
Mean±SD
95% CI
24±20
(18 to 30)
26±30
(18 to 35)
0.59 22±20
(17 to 27)
29±30
(19 to 39)
0.20
Mean difference (95% CI) −2.7%
(−12.8% to 7.3%)
−5.5%
(−17% to 4.2%)
Relative percentage 
change in potassium first 
episode (N)‡
18 23 23 18
Mean±SD
95% CI
25±20
(16 to 34)
30±20
(19 to 41)
0.51 24±20
(16 to 31)
33±30
(20 to 46)
0.18
Baseline characteristics of patients in both arms are presented in table 2a. Both groups had similar baseline characteristics; however, the 
IVPR arm had a higher inotropic score compared with the EPR arm for ITT (8.5±9.1 vs 4.6±4.1, p=0.01 respectively) and actual treatment 
(8.4±8.8 vs 4.1±3.3, p=0.004 respectively) analysis. All values reported as mean±SD (95% CI).
*Mann–Whitney U test was used for comparison of episodes and events due to skewed distribution while change in potassium concentration 
and relative percentage change were compared using an independent sample t test.
†Change in potassium concentration calculated as last event K – first event K of an episode.
‡Relative percentage change calculated as (first K value of the episode – last K value of the episode)/first K value of the episode * 100.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.
group.bmj.com on May 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Rehman Siddiqu Nur, et al. BMJ Open 2017;7:e011179. doi:10.1136/bmjopen-2016-011179
Open Access
Comparable efficacy between enteral and intravenous 
potassium supplementation was initially demonstrated 
in a recent retrospective study.9 This retrospective 
study conducted by Moffet et al included 66 paediatric 
patients post congenital heart surgery who received 
399 blouses of potassium (266 intravenous and 233 
enteral). As a change of practice was advocated to 
encourage the use of enteral potassium supplemen-
tation before data collection for this retrospective 
study, the authors believe that the physician’s clinical 
Figure 2 Change in potassium concentration at the beginning and end of episode.
Table 3 Repeated measure analysis of change in serum potassium concentration in IVPR and EPR arms  (ITT)
Unadjusted Adjusted*
Coef. SE 95% CI p-value Coef. SE 95% CI p-value
Potassium concentration
Intervention
Oral K 0.02 0.05 −0.08 to 
0.13
0.66 0.01 0.05 −0.08 to 
0.10
0.86
Intravenous 
K
Ref Ref
Percentage change in potassium concentration*
Intervention
Oral K 0.10 1.89 −3.60 to 
3.80
0.95 0.30 1.90 −3.42 to 
4.03
0.87
Intravenous 
K
Ref Ref
Percentage change (per hour) in potassium concentration*
Intervention
Oral K −3.01 1.55 −6.11 to 
−0.003
0.05 1.16 1.50 −1.76 to 
4.08
0.44
Intravenous 
K
Ref
*Percentage change calculated as (previous K – current K)/previous K * 100.
EPR, enteral potassium replacement; IVPR, intravenous potassium replacement.
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experience and judgement may have skewed adminis-
tration of enteral potassium to less critically ill patients. 
Also, limitations associated with a retrospective review 
reduced the generalisability of findings of this study. 
Taking the above-mentioned limitations into consider-
ation, a prospective study with a predefined protocol 
and practices in place to reduce clinician to clinician 
variability is warranted.
Although equally efficacious in improving potassium 
levels, IVPR requires stringent monitoring by PCICU 
staff and the presence of a central line.9 Correcting 
potassium levels back to normal usually requires multiple 
replacements, making repeated access to the central line 
a necessity. This may lead to central line related infec-
tions.9 14 Also, transition to enteral supplementation from 
IVPR poses a challenge in some patients and central lines 
have to be kept in place longer than otherwise required 
for intravenous potassium supplementation.14 Another 
downside of using IVPR is that a large volume of fluid is 
required for the delivery of the desired dose of potassium 
with peripheral lines which is not preferable in postoper-
ative cardiac patients in whom clinicians aim to achieve 
negative fluid balance. However, enteral supplementa-
tion with comparable efficacy offers many advantages. 
It is easier to transition paediatric patients after surgery 
for congenital heart disease directly to enteral supple-
mentation and if required they can be discharged home 
on this supplementation. Moreover, use of enteral potas-
sium supplementation can lead to significant reduction 
in fluid administration, which is of great advantage as 
hypokalaemia is frequently a consequence of adminis-
tration of loop diuretics to treat fluid overload in these 
patients. Although, paediatric data regarding pharma-
cokinetics of enteral potassium supplementation are 
lacking, safety and efficacy of enteral supplementation 
of potassium in the adult population has been well 
established previously. One more potential advantage 
of administrating enteral potassium supplementation 
for treatment of hypokalaemia is its cost effectiveness.9 
Along with being ten times more costly than EPR at our 
institution, IVPR also requires central line utilisation, 
increased nursing time and syringe pump utilisation that 
further adds to the overall cost of potassium supplemen-
tation. Adverse events seen in the enteral arm mainly 
comprised episodes of vomiting seen in some partici-
pants at the beginning of the trial. This can be attributed 
to the sour taste the of formulation or inappropriately 
fast administration through the NG tube. The former 
can be taken care of by feeding through the NG tube 
or mixing the enteral potassium formulation with fruit 
juices. Other than these few episodes of vomiting, partic-
ipants in this trial tolerated enteral supplementation 
of potassium well. Given its equal efficacy, low adverse 
event profile and a potential benefit, EPR was shown to 
be an excellent alternative to IVPR as first-line therapy 
in our patient cohort.
GENERALISABILITY
EIPS included patients received in the PCICU after 
cardiac surgery. The mean age of participants was 4.7 
years, with the youngest child being 1 month and the 
oldest child being 14 years. The predominant surgical 
procedure was VSD repair surgery. We believe that the 
results of our study can be generalised to these patient 
populations. However, there were only two patients with 
severely low potassium levels (see definition) and patients 
with critically low potassium, that is <2.0 mmol/L, who 
were excluded from the trial, thus the results from this 
trial should be generalised with caution in patients with 
severely and critically low potassium levels. Further 
investigation is warranted to determine the safety profile 
of enteral potassium in these patients. Also, EIPS is a 
single-centre randomised study, with alternate week 
patient randomization, leading to potential significant 
selection and allocation bias and limiting generalis-
ability of the findings.
We used a more aggressive potassium replacement 
strategy, that is levels between 3.5 and 4.4 mmol/L, based 
on observations that higher potassium levels are required 
in cardiac patients.7 Though no episode of hyperkalaemia 
was noticed in our cohort, our study is not powered to 
comment on the safety of this strategy.
LIMITATIONS
EIPS is a single-centre, non-blinded equivalence study 
that may lead to observer bias. Blinding was not feasible 
in this trial owing to different routes of administration of 
the same supplementation (enteral vs intravenous) and 
different time interval for checking serum levels in each 
arm (1 hour after intravenous replacement and 2 hours 
after enteral replacement). Confounding factors, such 
as concomitant use of diuretics and inotropic agents 
during the episode, may have affected potassium metab-
olism. These factors were identified and were adjusted 
in the analysis.
An auto-analyser, located in PCICU, was used to 
measure point of care potassium levels in this trial. This 
might have been a potential limiting factor in our study. 
Central lab values, although being gold standard, could 
not be used as turnover time for each sample at our insti-
tution is about 4 hours. Central lab values were obtained 
only when a critically low or high value was seen on the 
auto-analyser testing. A strong correlation between two 
values had previously been established during daily prac-
tice at our PCICU.
Difference in severity of the patient’s condition 
(as depicted by difference in inotropic scores in the 
2 arms) may also have confounded our results. This 
was accounted for at a statistical level by adjusting for 
inotropic scores in the multivariate modelling and did 
not seem to affect the results.
Some participants got moved out of PCICU before 
completion of an episode of hypokalaemia. Patients 
could not be followed once they moved out of PCICU 
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to a step-down unit or floor as stringent monitoring for 
trial and point of care potassium levels was not available 
in floor settings. This does affect the generalisability of 
study. Routinely, patients who get moved to step-down 
units or floor receive oral potassium supplementation 
in our institution.
It is imperative to know that enteral potassium replace-
ment may not be possible in some patients due to 
gastrointestinal intolerance.
Lastly, our trial was also underpowered to detect 
difference in frequency of adverse effects between both 
arms. This limits inference of equivalence between the 
two modes when it comes to their safety/adverse events 
profile.
CONCLUSION
We found similar effectiveness of EPR or IVPR, as first-line 
therapy, in treating hypokalaemia in paediatric patients 
after surgery for congenital heart disease. EPR may be an 
equally efficacious alternative to treat hypokalaemia, as 
first-line therapy, in these patients.
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